Stocktoria
Immunome Inc. IMNM
Immunome Inc. (IMNM) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $6.9M at a -3060.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-12 | Wedbush | Outperform (reit) |
| 2026-05-28 | Truist Securities | Buy (main) |
| 2026-05-28 | Barclays | Overweight (init) |
| 2026-05-15 | Leerink Partners | Outperform (main) |
| 2026-05-13 | HC Wainwright & Co. | Buy (reit) |
| 2026-03-04 | Craig-Hallum | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.901 |
| Retained earnings / assets | -1.066 |
| EBIT / assets | -0.328 |
| Equity / liabilities | 12.987 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IMNM | Immunome Inc. | 3/9 | 13.87 | — | — |
| WHWK | Whitehawk Therapeutics, Inc. | 2/9 | 2.98 | — | -72.5% |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
| KYNB | KYNTRA BIO, INC. | 3/9 | — | 0.2 | -78.3% |
| KRRO | Korro Bio, Inc. | 2/9 | -13.3 | — | — |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
| ADAG | Adagene Inc. | 4/9 | -9.75 | — | — |
About Immunome Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
FAQ
Is IMNM financially healthy?
Immunome Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does IMNM pay a dividend?
No, Immunome Inc. does not currently pay a dividend.
How profitable is IMNM?
In FY2025, Immunome Inc. had a net margin of -3060.0% and a return on equity of -33.5%.
What is the analyst price target for IMNM?
The average Wall-Street price target for Immunome Inc. is $35.77, about 27.8% above the recent price, from 13 analysts.
Is IMNM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Immunome Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.